Use of riluzole prodrugs to treat ataxias

Patent metadata

Field	Value
Publication number	US-12102618-B2
Application number	US-202318353840-A
Country	US
Kind code	B2
Filing date	Jul 17, 2023
Priority date	Nov 12, 2017
Publication date	Oct 1, 2024
Grant date	Oct 1, 2024

Abstract

Disclosed are methods of treating ataxia by administering to a patient in need thereof a riluzole prodrug such as troriluzole. Pharmaceutical compositions and kits including the riluzole prodrugs are also disclosed.

First claim

What is claimed is:

1. A method of treating spinocerebellar ataxia type 3 in a patient, comprising administering to the patient in need of such treatment a therapeutically effective amount of a riluzole prodrug having the following formula:

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the treatment provides an improvement in the patient's total SARA score of at least 0.8, or 0.9, or 1.0, or 1.1, or 1.2, or 1.3, or 1.4, or 1.5, or 1.6, or 1.7, or 1.8, or 1.9, or 2.0, or greater.

3. The method of claim 1 , wherein the riluzole prodrug is administered to the patient at a dosage of from about 17.5 to 200 mg per day.

4. The method of claim 3 , wherein the riluzole prodrug is administered to the patient at a dosage of about 17.5, or 35, or 70, or 100, or 140, or 200 mg per day.

5. The method of claim 4 , wherein the riluzole prodrug is administered to the patient at a dosage of 200 mg, once per day.

6. The method of claim 4 , wherein the riluzole prodrug is administered to the patient at a dosage of 140 mg, once per day.

7. The method of claim 1 , wherein the riluzole prodrug is administered to the patient once per day.

8. The method of claim 1 , wherein the riluzole prodrug is administered to the patient twice per day.

9. The method of claim 1 , wherein the riluzole prodrug is administered to the patient in the form of a capsule.

10. The method of claim 1 , wherein the riluzole prodrug is administered to the patient in the form of a tablet.

11. The method of claim 1 , wherein the riluzole prodrug is administered to the patient for a duration of from about 8 weeks to 48 weeks.

12. The method of claim 1 , wherein the riluzole prodrug is administered to the patient at a dosage of about 200 mg or less per day.

13. The method of claim 1 , wherein the riluzole prodrug is administered to the patient once daily.

Assignees

• Biohaven Therapeutics Ltd

Inventors

• Coric Vladimir
• Berman Robert
• Beiner Melissa
• L'Italien Gilbert

Classifications

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61K38/06

  Tripeptides · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K9/48

  Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)} · CPC title

• A61K9/20

  Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)} · CPC title